2024 Q1 Form 10-K Financial Statement
#000140464424000020 Filed on March 18, 2024
Income Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $5.238M | -$1.281M | $11.19M |
YoY Change | 30.07% | -130.14% | -37.73% |
% of Gross Profit | |||
Research & Development | $13.54M | $36.51M | $44.39M |
YoY Change | 76.09% | 265.1% | 7.94% |
% of Gross Profit | |||
Depreciation & Amortization | $800.0K | $2.782M | $3.300M |
YoY Change | 143.16% | 655.98% | 111.4% |
% of Gross Profit | |||
Operating Expenses | $18.78M | $31.82M | $55.58M |
YoY Change | 24.08% | 123.25% | -5.95% |
Operating Profit | -$18.78M | -$55.58M | |
YoY Change | 24.08% | -5.95% | |
Interest Expense | $3.000K | -$29.00K | $12.00K |
YoY Change | -99.68% | -103.59% | -99.24% |
% of Operating Profit | |||
Other Income/Expense, Net | -$459.0K | -$13.00K | -$28.00K |
YoY Change | 3178.57% | 550.0% | -33.33% |
Pretax Income | -$16.92M | -$15.50M | -$36.32M |
YoY Change | 19.13% | 15.3% | -36.93% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$16.92M | $13.65M | -$36.30M |
YoY Change | 19.13% | -201.55% | -36.93% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$1.00 | $27.76 | |
Diluted Earnings Per Share | -$1.00 | $2.93 | -$2.83 |
COMMON SHARES | |||
Basic Shares Outstanding | 12.85M shares | 9.398M shares | |
Diluted Shares Outstanding | 16.90M shares | 4.657M shares |
Balance Sheet
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $169.5M | $197.2M | $197.2M |
YoY Change | 103.19% | 104.55% | 104.55% |
Cash & Equivalents | $150.1M | $148.2M | $148.2M |
Short-Term Investments | $19.39M | $48.95M | $48.95M |
Other Short-Term Assets | $1.254M | $1.095M | $3.191M |
YoY Change | -43.0% | -60.18% | 16.04% |
Inventory | |||
Prepaid Expenses | $2.765M | $1.496M | |
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $174.1M | $200.3M | $200.3M |
YoY Change | 103.35% | 102.1% | 102.1% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $16.48M | $17.17M | $20.95M |
YoY Change | 561.91% | 8.16% | 31.96% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $743.0K | $764.0K | $1.272M |
YoY Change | -17.9% | -18.38% | 35.9% |
Total Long-Term Assets | $21.21M | $22.23M | $22.23M |
YoY Change | 65.39% | 32.18% | 32.18% |
TOTAL ASSETS | |||
Total Short-Term Assets | $174.1M | $200.3M | $200.3M |
Total Long-Term Assets | $21.21M | $22.23M | $22.23M |
Total Assets | $195.4M | $222.6M | $222.6M |
YoY Change | 98.41% | 91.96% | 91.96% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.522M | $2.596M | $2.596M |
YoY Change | -71.92% | -72.81% | 443.1% |
Accrued Expenses | $6.824M | $17.50M | $20.05M |
YoY Change | 376.87% | 1172.36% | 92.01% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $43.00K | $42.00K | $42.00K |
YoY Change | -85.86% | -70.0% | -70.0% |
Total Short-Term Liabilities | $11.82M | $22.97M | $22.97M |
YoY Change | 65.15% | 107.67% | 107.67% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $53.00K | $65.00K | $65.00K |
YoY Change | 657.14% | -72.1% | -72.1% |
Other Long-Term Liabilities | $203.0K | $203.0K | $13.51M |
YoY Change | -97.96% | -98.03% | 30.9% |
Total Long-Term Liabilities | $203.0K | $203.0K | $13.58M |
YoY Change | -97.96% | -98.08% | 28.62% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $11.82M | $22.97M | $22.97M |
Total Long-Term Liabilities | $203.0K | $203.0K | $13.58M |
Total Liabilities | $24.57M | $36.55M | $36.55M |
YoY Change | 43.68% | 69.08% | 69.08% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$204.1M | -$187.2M | |
YoY Change | -56.13% | -58.5% | |
Common Stock | $0.00 | $0.00 | |
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $170.8M | $186.0M | $186.0M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $195.4M | $222.6M | $222.6M |
YoY Change | 98.41% | 91.96% | 91.96% |
Cashflow Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$16.92M | $13.65M | -$36.30M |
YoY Change | 19.13% | -201.55% | -36.93% |
Depreciation, Depletion And Amortization | $800.0K | $2.782M | $3.300M |
YoY Change | 143.16% | 655.98% | 111.4% |
Cash From Operating Activities | -$21.70M | -$30.07M | -$51.40M |
YoY Change | 66.5% | 175.06% | 12.7% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $65.00K | -$229.0K | $321.0K |
YoY Change | -84.49% | -320.19% | -71.08% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $30.00M | $16.73M | $25.96M |
YoY Change | 169.66% | 95.17% | -144.74% |
Cash From Investing Activities | $29.94M | $16.96M | $25.64M |
YoY Change | 179.61% | 100.27% | -143.35% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $92.34M | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -$6.524M | 92.84M | $92.48M |
YoY Change | 9784.85% | 515688.89% | 57342.24% |
NET CHANGE | |||
Cash From Operating Activities | -$21.70M | -30.07M | -$51.40M |
Cash From Investing Activities | $29.94M | 16.96M | $25.64M |
Cash From Financing Activities | -$6.524M | 92.84M | $92.48M |
Net Change In Cash | $1.761M | 79.73M | $66.70M |
YoY Change | -173.59% | -3356.82% | -163.78% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$21.70M | -$30.07M | -$51.40M |
Capital Expenditures | $65.00K | -$229.0K | $321.0K |
Free Cash Flow | -$21.77M | -$29.84M | -$51.72M |
YoY Change | 61.8% | 170.39% | 10.71% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023 | dei |
Entity File Number
EntityFileNumber
|
001-36327 | |
CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
Neurogene Inc. | |
CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
98-0542593 | |
CY2023 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
5th Floor | |
CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
New York | |
CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NY | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
10011 | |
CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
508-3568 | |
CY2023 | dei |
Trading Symbol
TradingSymbol
|
NGNE | |
CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2023 | dei |
Security12b Title
Security12bTitle
|
Common stock, par value $0.000001 per share | |
CY2023 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001404644 | |
CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023Q4 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.25 | |
CY2023 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
CY2023 | ngne |
Collaborative Arrangement Rights And Obligations Effective Term Scenario One
CollaborativeArrangementRightsAndObligationsEffectiveTermScenarioOne
|
P6M | |
CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
535 W 24th St. | |
CY2023 | dei |
City Area Code
CityAreaCode
|
855 | |
CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Public Float
EntityPublicFloat
|
33350835 | usd |
CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
12852985 | shares |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
34 | |
CY2022 | dei |
Auditor Firm
AuditorFirmId
|
42 | |
CY2023 | dei |
Auditor Name
AuditorName
|
Deloitte & Touche LLP | |
CY2023 | dei |
Auditor Location
AuditorLocation
|
Seattle, WA | |
CY2022 | dei |
Auditor Name
AuditorName
|
Ernst & Young LLP | |
CY2022 | dei |
Auditor Location
AuditorLocation
|
Stamford, Connecticut | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
148210000 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
82021000 | usd |
CY2023Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
48947000 | usd |
CY2022Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
0 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3191000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2698000 | usd |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
200348000 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
84719000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17174000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
20115000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3681000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
4344000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
98000 | usd |
CY2022Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
87000 | usd |
CY2023Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
508000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
764000 | usd |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Assets
Assets
|
222573000 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
109265000 | usd |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2596000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
625000 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
17495000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5324000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2559000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
678000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
42000 | usd |
CY2022Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
24000 | usd |
CY2023Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
|
281000 | usd |
CY2022Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
22973000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
6651000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
12302000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
3921000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
65000 | usd |
CY2022Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
66000 | usd |
CY2023Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
|
1006000 | usd |
CY2022Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
203000 | usd |
CY2022Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
36549000 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
10638000 | usd |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2023Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
0 | usd |
CY2022Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
244366000 | usd |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
50000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
0 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
12823665 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
12823665 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
0 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
0 | shares |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
0 | usd |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
0 | usd |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
373178000 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
5098000 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-187154000 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-150837000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
186024000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-145739000 | usd |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
222573000 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
109265000 | usd |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
44394000 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
47505000 | usd |
CY2023 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11189000 | usd |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9012000 | usd |
CY2023 | us-gaap |
Operating Expenses
OperatingExpenses
|
55583000 | usd |
CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
56517000 | usd |
CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-55583000 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-56517000 | usd |
CY2023 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2951000 | usd |
CY2022 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1337000 | usd |
CY2023 | us-gaap |
Interest Expense
InterestExpense
|
12000 | usd |
CY2022 | us-gaap |
Interest Expense
InterestExpense
|
2000 | usd |
CY2023 | ngne |
Asset Acquisition Bargain Purchase Gain Recognized Amount
AssetAcquisitionBargainPurchaseGainRecognizedAmount
|
16355000 | usd |
CY2022 | ngne |
Asset Acquisition Bargain Purchase Gain Recognized Amount
AssetAcquisitionBargainPurchaseGainRecognizedAmount
|
0 | usd |
CY2023 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
28000 | usd |
CY2022 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
7000 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36317000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55189000 | usd |
CY2023Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
27.76 | |
CY2023Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
491867 | shares |
CY2023Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
2.93 | |
CY2023Q4 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
4656947 | shares |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-91875000 | usd |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1252000 | usd |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1252000 | usd |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
91000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
73000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
73000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55189000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55189000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-145739000 | usd |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1418000 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
168000 | usd |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
6946000 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
88056000 | usd |
CY2023 | ngne |
Adjustments To Additional Paid In Capital Asset Acquisition Transaction Costs
AdjustmentsToAdditionalPaidInCapitalAssetAcquisitionTransactionCosts
|
4140000 | usd |
CY2023 | us-gaap |
Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
|
38212000 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36317000 | usd |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
186024000 | usd |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36317000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55189000 | usd |
CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1418000 | usd |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1252000 | usd |
CY2023 | ngne |
Asset Acquisition Bargain Purchase Gain Recognized Amount
AssetAcquisitionBargainPurchaseGainRecognizedAmount
|
16355000 | usd |
CY2022 | ngne |
Asset Acquisition Bargain Purchase Gain Recognized Amount
AssetAcquisitionBargainPurchaseGainRecognizedAmount
|
0 | usd |
CY2023 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3262000 | usd |
CY2022 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3196000 | usd |
CY2023 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
663000 | usd |
CY2022 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
608000 | usd |
CY2023 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
35000 | usd |
CY2022 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
4000 | usd |
CY2023 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
105000 | usd |
CY2022 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
0 | usd |
CY2023 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-326000 | usd |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-716000 | usd |
CY2023 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
764000 | usd |
CY2022 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | usd |
CY2023 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
667000 | usd |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3607000 | usd |
CY2023 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-3574000 | usd |
CY2022 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
806000 | usd |
CY2023 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-678000 | usd |
CY2022 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-610000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-51422000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-52824000 | usd |
CY2023 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
321000 | usd |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2230000 | usd |
CY2023 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
22243000 | usd |
CY2022 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
0 | usd |
CY2023 | ngne |
Payments Of Merger Related Costs Investing Activities
PaymentsOfMergerRelatedCostsInvestingActivities
|
1285000 | usd |
CY2022 | ngne |
Payments Of Merger Related Costs Investing Activities
PaymentsOfMergerRelatedCostsInvestingActivities
|
0 | usd |
CY2023 | us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
5000000 | usd |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
0 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
25637000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2230000 | usd |
CY2023 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
92343000 | usd |
CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | usd |
CY2023 | us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
0 | usd |
CY2022 | us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
66459000 | usd |
CY2023 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
168000 | usd |
CY2022 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
73000 | usd |
CY2023 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
29000 | usd |
CY2022 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
1000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
92482000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
66531000 | usd |
CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
66697000 | usd |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
11477000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82021000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
70544000 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
148718000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82021000 | usd |
CY2023 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
46000 | usd |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
91000 | usd |
CY2023 | ngne |
Noncash Or Part Noncash Acquisition Operating Lease Liabilities Acquired
NoncashOrPartNoncashAcquisitionOperatingLeaseLiabilitiesAcquired
|
10940000 | usd |
CY2022 | ngne |
Noncash Or Part Noncash Acquisition Operating Lease Liabilities Acquired
NoncashOrPartNoncashAcquisitionOperatingLeaseLiabilitiesAcquired
|
0 | usd |
CY2023 | ngne |
Noncash Or Part Noncash Acquisition Contingent Consideration Acquired
NoncashOrPartNoncashAcquisitionContingentConsiderationAcquired
|
1287000 | usd |
CY2022 | ngne |
Noncash Or Part Noncash Acquisition Contingent Consideration Acquired
NoncashOrPartNoncashAcquisitionContingentConsiderationAcquired
|
0 | usd |
CY2023 | us-gaap |
Noncash Or Part Noncash Acquisition Other Liabilities Assumed1
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
|
10110000 | usd |
CY2022 | us-gaap |
Noncash Or Part Noncash Acquisition Other Liabilities Assumed1
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
|
0 | usd |
CY2023 | ngne |
Noncash Or Part Noncash Acquisition Value Of Short Term Investments Acquired
NoncashOrPartNoncashAcquisitionValueOfShortTermInvestmentsAcquired
|
53900000 | usd |
CY2023 | ngne |
Noncash Or Part Noncash Acquisition Value Of Other Monetary Assets Acquired
NoncashOrPartNoncashAcquisitionValueOfOtherMonetaryAssetsAcquired
|
800000 | usd |
CY2023 | us-gaap |
Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
|
54661000 | usd |
CY2022 | us-gaap |
Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
|
0 | usd |
CY2023 | us-gaap |
Stock Issued1
StockIssued1
|
38212000 | usd |
CY2022 | us-gaap |
Stock Issued1
StockIssued1
|
0 | usd |
CY2023 | ngne |
Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
4287000 | usd |
CY2022 | ngne |
Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
0 | usd |
CY2023 | ngne |
Asset Acquisition Costs Incurred During Noncash Or Partial Noncash Transaction
AssetAcquisitionCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
2855000 | usd |
CY2022 | ngne |
Asset Acquisition Costs Incurred During Noncash Or Partial Noncash Transaction
AssetAcquisitionCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
0 | usd |
CY2023 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
244366000 | usd |
CY2022 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | usd |
CY2023 | us-gaap |
Interest Paid Net
InterestPaidNet
|
12000 | usd |
CY2022 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2000 | usd |
CY2023Q4 | ngne |
Reverse Merger Conversion Ratio
ReverseMergerConversionRatio
|
0.0756 | shares |
CY2023Q4 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
7231747 | shares |
CY2023 | ngne |
Asset Acquisition Percentage Of Net Proceeds Before Closing
AssetAcquisitionPercentageOfNetProceedsBeforeClosing
|
1 | |
CY2023 | ngne |
Asset Acquisition Percentage Of Net Proceeds Post Closing
AssetAcquisitionPercentageOfNetProceedsPostClosing
|
0.80 | |
CY2023Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
|
300000 | usd |
CY2023Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
|
1000000 | usd |
CY2023 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Risks and Uncertainties </span><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of pre-clinical studies, clinical studies and clinical trials, the need to obtain marketing approval for its drug candidates and its consumer products, fluctuations in operating results, economic pressure impacting therapeutic pricing, dependence on key personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to transition from pilot scale manufacturing to large scale production.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has funded its operations primarily with proceeds from the sales of equity securities and has incurred significant recurring losses, including net losses of $36.3 million and $55.2 million for the years ended December 31, 2023 and 2022, respectively. In addition, the Company used cash in operations of $51.4 million and $52.8 million for the years ended December 31, 2023 and 2022, respectively, and had an accumulated deficit of $187.2 million as of December 31, 2023. Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had cash and cash equivalents of approximately $148.2 million. On December 18, 2023, the Company closed on the merger with Neoleukin Therapeutics, Inc. (see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Merger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and a Pre-Closing Financing (see Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization and Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company expects its available cash and cash equivalents on hand as of the issuance date </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these financial statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be sufficient to fund its obligations as they become due for at least one year beyond the issuance date of these financial statements. As a result of the reverse merger with Neoleukin Therapeutics, the Company assumed an ATM or “at-the-market” Equity Offering Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc., as agent (“BofA”), pursuant to which the Company may offer and sell, from time to time through BofA, shares of the Company’s common stock, having an aggregate offering price of up to $40.0 million. In March 2024, the Company terminated the ATM. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company’s operations, a sale of assets, or other alternatives with strategic or financial partners. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></div> | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36300000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55200000 | usd |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-51400000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-52800000 | usd |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-187200000 | usd |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
148200000 | usd |
CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing these financial statements, management used significant estimates in the following areas, among others: recoverability of the Company’s net deferred tax assets and related valuation allowance, useful lives and recoverability of property and equipment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining the Incremental Borrowing Rate (“IBR”) for calculating lease liabilities and related right-of-use (“ROU”) assets and finance lease assets, clinical trial accruals, accrual estimates for all CVRs, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the value attributed to employee stock options and other stock-based awards and valuation of common stock. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.</span></div> | |
CY2023 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
148210000 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
82021000 | usd |
CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
508000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
148718000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82021000 | usd |
CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
500000 | usd |
CY2023 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash and cash equivalent accounts, at times, may exceed federally insured limits. As of December 31, 2023, the Company had $147.7 million in excess of the federally insured limits. The Company places its cash in financial institutions that management believes to be of high credit quality.</span></div> | |
CY2023Q4 | ngne |
Cash And Cash Equivalents At Or Above Fdic Insurance Limits
CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits
|
147700000 | usd |
CY2023Q4 | us-gaap |
Debt Securities Held To Maturity Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAllowanceForCreditLoss
|
0 | usd |
CY2023Q4 | us-gaap |
Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
|
300000 | usd |
CY2022Q4 | us-gaap |
Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
|
400000 | usd |
CY2023 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
200000 | usd |
CY2022 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
200000 | usd |
CY2023 | us-gaap |
Capitalized Computer Software Impairments1
CapitalizedComputerSoftwareImpairments1
|
0 | usd |
CY2022 | us-gaap |
Capitalized Computer Software Impairments1
CapitalizedComputerSoftwareImpairments1
|
0 | usd |
CY2022 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
0 | usd |
CY2023 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
0 | usd |
CY2023Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
|
300000 | usd |
CY2023Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
|
1000000 | usd |
CY2023Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
900000 | usd |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
|
0 | usd |
CY2023Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
13654000 | usd |
CY2023Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
491867 | shares |
CY2023Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
27.76 | |
CY2023Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
13654000 | usd |
CY2023Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
491867 | shares |
CY2023Q4 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
4063361 | shares |
CY2023Q4 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
101719 | shares |
CY2023Q4 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
4656947 | shares |
CY2023Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
2.93 | |
CY2023Q4 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
541180 | shares |
CY2023Q4 | ngne |
Reverse Merger Conversion Ratio
ReverseMergerConversionRatio
|
0.0756 | shares |
CY2023Q4 | ngne |
Refunds And Other Receivables Current
RefundsAndOtherReceivablesCurrent
|
600000 | usd |
CY2022Q4 | ngne |
Refunds And Other Receivables Current
RefundsAndOtherReceivablesCurrent
|
990000 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1496000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1078000 | usd |
CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
1095000 | usd |
CY2022Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
630000 | usd |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3191000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2698000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
25183000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
24882000 | usd |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
8009000 | usd |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4767000 | usd |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17174000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
20115000 | usd |
CY2023 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3300000 | usd |
CY2022 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3200000 | usd |
CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3496000 | usd |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3357000 | usd |
CY2023Q4 | ngne |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
4895000 | usd |
CY2022Q4 | ngne |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
1800000 | usd |
CY2023Q4 | ngne |
Accrued Severance Bonus And Retention Costs Current
AccruedSeveranceBonusAndRetentionCostsCurrent
|
2476000 | usd |
CY2022Q4 | ngne |
Accrued Severance Bonus And Retention Costs Current
AccruedSeveranceBonusAndRetentionCostsCurrent
|
0 | usd |
CY2023Q4 | ngne |
Accrued Stock Issuance Costs Current
AccruedStockIssuanceCostsCurrent
|
3334000 | usd |
CY2022Q4 | ngne |
Accrued Stock Issuance Costs Current
AccruedStockIssuanceCostsCurrent
|
0 | usd |
CY2023Q4 | ngne |
Accrued Asset Acquisition Transaction Costs Current
AccruedAssetAcquisitionTransactionCostsCurrent
|
2557000 | usd |
CY2022Q4 | ngne |
Accrued Asset Acquisition Transaction Costs Current
AccruedAssetAcquisitionTransactionCostsCurrent
|
0 | usd |
CY2023Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
737000 | usd |
CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
167000 | usd |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
17495000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5324000 | usd |
CY2023 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1037000 | usd |
CY2022 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1037000 | usd |
CY2023 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
35000 | usd |
CY2022 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
4000 | usd |
CY2023 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
12000 | usd |
CY2022 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
2000 | usd |
CY2023 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
178000 | usd |
CY2022 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
196000 | usd |
CY2023 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
80000 | usd |
CY2022 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
74000 | usd |
CY2023 | us-gaap |
Lease Cost
LeaseCost
|
1342000 | usd |
CY2022 | us-gaap |
Lease Cost
LeaseCost
|
1313000 | usd |
CY2023 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
42000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
3862000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3964000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3672000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
3235000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
3294000 | usd |
CY2023Q4 | ngne |
Lessee Operating Lease Liability To Be Paid Year Six
LesseeOperatingLeaseLiabilityToBePaidYearSix
|
616000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
18643000 | usd |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
3782000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
14861000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
51000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
50000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
15000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
6000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
1000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
123000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
16000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
107000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3681000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
4344000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2559000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
678000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
12302000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
3921000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
14861000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4599000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
|
98000 | usd |
CY2022Q4 | us-gaap |
Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
|
87000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
42000 | usd |
CY2022Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
24000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
65000 | usd |
CY2022Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
66000 | usd |
CY2023Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
107000 | usd |
CY2022Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
90000 | usd |
CY2023 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1051000 | usd |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1039000 | usd |
CY2022 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
3000 | usd |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y10M17D | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y8M19D | |
CY2023Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y6M10D | |
CY2022Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y5M19D | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0972 | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0886 | |
CY2023Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.1149 | |
CY2022Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.1145 | |
CY2023 | us-gaap |
Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
|
1300000 | usd |
CY2023Q4 | ngne |
Asset Acquisition Contingent Consideration Arrangements Range Of Outcomes Value Low
AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueLow
|
1300000 | usd |
CY2023Q4 | ngne |
Asset Acquisition Contingent Consideration Arrangements Range Of Outcomes Value High
AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh
|
19500000 | usd |
CY2023 | us-gaap |
Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
|
1300000 | usd |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
|
281000 | usd |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
|
598000 | usd |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
|
408000 | usd |
CY2023Q4 | us-gaap |
Contractual Obligation
ContractualObligation
|
1287000 | usd |
CY2023 | ngne |
Collaborative Arrangement Rights And Obligations Effective Term Scenario Two
CollaborativeArrangementRightsAndObligationsEffectiveTermScenarioTwo
|
P30D | |
CY2023Q4 | ngne |
Accrued Severance Bonus And Retention Costs Current
AccruedSeveranceBonusAndRetentionCostsCurrent
|
2500000 | usd |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
50000000 | shares |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2023Q4 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
13505271 | shares |
CY2023Q4 | ngne |
Reverse Merger Conversion Ratio
ReverseMergerConversionRatio
|
0.0756 | shares |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7231747 | shares |
CY2023Q4 | ngne |
Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
|
1825635 | shares |
CY2023 | ngne |
Convertible Preferred Stock Non Cumulative Dividends Per Dollar Amount
ConvertiblePreferredStockNonCumulativeDividendsPerDollarAmount
|
0.18 | |
CY2023 | us-gaap |
Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
|
0 | usd |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | shares |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
CY2023Q4 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
10472635 | shares |
CY2023 | ngne |
Percentage Of Outstanding Stock Per Stockholder Maximum
PercentageOfOutstandingStockPerStockholderMaximum
|
0.0999 | |
CY2023 | ngne |
Percentage Of Outstanding Stock Per Stockholder Upon Notice Maximum
PercentageOfOutstandingStockPerStockholderUponNoticeMaximum
|
0.1999 | |
CY2023 | ngne |
Class Of Warrant Or Right Notice Period
ClassOfWarrantOrRightNoticePeriod
|
P61D | |
CY2023 | ngne |
Common Stock Maximum Holding Percentage
CommonStockMaximumHoldingPercentage
|
0.0499 | |
CY2023Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3061555 | shares |
CY2022Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
107085760 | shares |
CY2023Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
0.0756 | shares |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
|
0.04 | |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1418000 | usd |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1252000 | usd |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
468632 | shares |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
13.23 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y4M13D | |
CY2023 | ngne |
Share Based Compensation Arrangement By Share Based Payment Award Options Assumption In Connection With Reverse Merger
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumptionInConnectionWithReverseMerger
|
215207 | shares |
CY2023 | ngne |
Share Based Compensation Arrangement By Share Based Payment Award Options Assumption In Connection With Reverse Merger Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumptionInConnectionWithReverseMergerWeightedAverageExercisePrice
|
77.20 | |
CY2023 | ngne |
Share Based Compensation Arrangement By Share Based Payment Award Options Assumption Of Options In Connection With The Reverse Merger Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumptionOfOptionsInConnectionWithTheReverseMergerWeightedAveragePrice
|
2.50 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
183391 | shares |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
18.91 | |
CY2023 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
20348 | shares |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
8.24 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
23049 | shares |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
20.34 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
823833 | shares |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
31.43 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y10M20D | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
527053 | shares |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
38.42 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P4Y8M23D | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2600000 | usd |
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
2300000 | usd |
CY2023Q4 | ngne |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue
|
300000 | usd |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.99 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
15.37 | |
CY2023Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
3200000 | usd |
CY2022 | ngne |
Effective Income Tax Rate Reconciliation Bargain Purchase Gain Percent
EffectiveIncomeTaxRateReconciliationBargainPurchaseGainPercent
|
0 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.350 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.235 | |
CY2023 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
CY2022 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-36317000 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-55189000 | usd |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-36317000 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-55189000 | usd |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.008 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
-0.001 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
-0.005 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
-0.004 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.058 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.030 | |
CY2023 | ngne |
Effective Income Tax Rate Reconciliation Bargain Purchase Gain Percent
EffectiveIncomeTaxRateReconciliationBargainPurchaseGainPercent
|
0.095 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
60287000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
25253000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
9765000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3681000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
802000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
727000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2952000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
107000 | usd |
CY2023Q4 | ngne |
Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
|
778000 | usd |
CY2022Q4 | ngne |
Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
|
298000 | usd |
CY2023Q4 | ngne |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
3157000 | usd |
CY2022Q4 | ngne |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
995000 | usd |
CY2023Q4 | ngne |
Deferred Tax Assetts Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssettsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
22134000 | usd |
CY2022Q4 | ngne |
Deferred Tax Assetts Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssettsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
8271000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
99875000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
39332000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
98926000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
38168000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
949000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
1164000 | usd |
CY2023Q4 | ngne |
Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
|
152000 | usd |
CY2022Q4 | ngne |
Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
|
224000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
|
797000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
|
940000 | usd |
CY2023Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
949000 | usd |
CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
1164000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | usd |
CY2023 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
60700000 | usd |
CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
13000000 | usd |
CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
13000000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
38168000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
25195000 | usd |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
98926000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
38168000 | usd |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
2600000 | usd |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
1100000 | usd |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1108000 | usd |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
632000 | usd |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
574000 | usd |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
476000 | usd |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
929000 | usd |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
0 | usd |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2611000 | usd |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1108000 | usd |
CY2023 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
500000 | usd |
CY2022 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
500000 | usd |
CY2023 | ngne |
Defined Contribution Plan Employer Contributions Vesting Period
DefinedContributionPlanEmployerContributionsVestingPeriod
|
P5Y | |
CY2023 | ngne |
Cares Act Employee Retention Credits
CARESActEmployeeRetentionCredits
|
900000 | usd |
CY2023Q4 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
CY2023Q4 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
CY2023Q4 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2023Q4 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false |